Effects of NMDA receptor antagonists: Implications for the pathophysiology of schizophrenia [3]

Archives of General Psychiatry

Volumn 59, Issue 7, 2002, Pages 663-664

  Krystal, John H ^a   Anand, Amit ^a   Moghaddam, Bita ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; GLUTAMIC ACID; KETAMINE; LAMOTRIGINE; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE;

BRAIN REGION; COGNITION; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG ANTAGONISM; DRUG MECHANISM; HUMAN; LETTER; LOCOMOTION; NEUROTOXICITY; PATHOPHYSIOLOGY; SCHIZOPHRENIA; WORKING MEMORY;

EID: 0036305335     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.59.7.663     Document Type: Letter

References (16)

1. Attenuation of neuropsychiatric effects of ketamine with lamotrigine: Support for hyperglutamatergic effects of NMDA receptor antagonists
2. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
3. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats
4. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia
5. Behavioural and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in rats
6. Regulation of neurotransmitter release by metabotropic glutamate receptors
7. NMDA-dependent modulation of CAi local circuit inhibition
8. Involvement of gamma-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex
9. Serotonin model of schizophrenia: Emerging role of glutamate mechanisms
10. The role of glutamate in epilepsy and other CNS disorders
11. Lamotrigine prevents NMDA antagonist neurotoxicity
12. Increased dopamine transmission in schizophrenia: Relationship to illness phases
13. Amphetamine pretreatment reduces attention defecits, but not psychosis, produced by ketamine in health human subjects
14. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders
15. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia
16. A preliminary dosescalation trial of CX-516 (ampakine) added to clozapine in schizophrenia